Strong confidence in Evobright’s business model

With their decision to contribute around 400,000 euros from their own funds in the first fiscal year, the shareholders of Evobright underline their conviction that they are on the right track with Evobright’s therapy concept and business model.

“This is money well spent,” comments Evobright’s CEO, Dr. Künkele on this investment. “Comparable therapeutic concepts are rewarded by buyers in the pharmaceutical industry with 50-100 million euros in upfront payments, as well as further milestone and royalty payments that add up to several billion dollars. What I particularly like about this investment is that my contribution already comes from royalties on therapeutic antibodies, and that both founders have agreed to also reinvest a large portion of our share of Evobright’s profits in our next therapeutic concepts.” “Of course, our share of the business will be diluted as the financing rounds progress,” notes Dr. Baumann, Evobright’s COO. “However, having additional investors share in Evobright’s profits has the positive effect of increasing investor confidence in our ideas and capabilities as we succeed, making it easier for us to grow our company over the long term.”